NYSE - Nasdaq Real Time Price USD

Annovis Bio, Inc. (ANVS)

1.5300
-0.0700
(-4.37%)
At close: May 9 at 4:00:02 PM EDT
1.6000
+0.07
+(4.58%)
After hours: May 9 at 7:48:03 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
26,694.9280
26,694.9280
45,035.0110
25,511.2790
14,500.4670
Operating Income
-26,694.9280
-26,694.9280
-45,035.0110
-25,511.2790
-14,500.4670
Net Non Operating Interest Income Expense
-1,521.3400
-1,521.3400
667.8980
182.7120
13.3350
Other Income Expense
3,625.8930
3,625.8930
-11,837.2000
--
--
Pretax Income
-24,590.3750
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Net Income Common Stockholders
-24,590.3750
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Average Dilution Earnings
-3,625.8930
-3,625.8930
0
--
--
Diluted NI Available to Com Stockholders
-28,216.2680
-28,216.2680
-56,204.3130
-25,328.5670
-14,487.1320
Basic EPS
-3.97
-2.02
-6.23
-3.10
-1.90
Diluted EPS
-4.22
-2.31
-6.23
-3.10
-1.90
Basic Average Shares
11,027.2960
12,182.4750
9,023.1380
8,162.3260
7,626.2780
Diluted Average Shares
11,077.2230
12,235.4440
9,023.1380
8,162.3260
7,626.2780
Total Operating Income as Reported
-26,694.9280
-26,694.9280
-45,035.0110
-25,511.2790
-14,537.2210
Total Expenses
26,694.9280
26,694.9280
45,035.0110
25,511.2790
14,500.4670
Net Income from Continuing & Discontinued Operation
-24,590.3750
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Normalized Income
-28,216.2680
-28,216.2680
-44,367.1130
-25,328.5670
-14,487.1320
Interest Income
331.8490
331.8490
667.8980
182.7120
13.3350
Net Interest Income
-1,521.3400
-1,521.3400
667.8980
182.7120
13.3350
EBIT
-26,694.9280
-26,694.9280
-45,035.0110
-25,511.2790
-14,500.4670
EBITDA
-26,694.9280
-26,694.9280
-45,035.0110
-25,511.2790
-14,500.4670
Net Income from Continuing Operation Net Minority Interest
-24,590.3750
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Total Unusual Items Excluding Goodwill
3,625.8930
3,625.8930
-11,837.2000
--
--
Total Unusual Items
3,625.8930
3,625.8930
-11,837.2000
--
--
Normalized EBITDA
-30,320.8210
-30,320.8210
-33,197.8110
-25,511.2790
-14,500.4670
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/29/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AVXL Anavex Life Sciences Corp.
8.25
-3.62%
 
SAVA Cassava Sciences, Inc.
1.7700
+4.12%
 
ACIU AC Immune SA
1.6800
+1.20%
 
INMB INmune Bio, Inc.
6.97
-1.69%
 
ANNX Annexon, Inc.
1.6000
-5.88%
 
ALT Altimmune, Inc.
5.59
-3.62%
 
MIST Milestone Pharmaceuticals Inc.
1.1100
-7.50%
 
AXSM Axsome Therapeutics, Inc.
107.76
-1.01%
 
CGTX Cognition Therapeutics, Inc.
0.3011
-8.76%
 
CADL Candel Therapeutics, Inc.
4.8100
+1.05%